2023. Deucravacitinib in Plaque Psoriasis: Maintenance of Response Over 3 Years in the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s241. DOI:https://doi.org/10.25251/skin.7.supp.241.